The Huntington News2d
City installs new pedestrian plaza on Westland Avenue
The BTD officially opened the Edgerly Plaza, a pedestrian walkway, in front of Whole Foods on Westland Avenue Oct. 30.
Zacks.com on MSN3d
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...
PMLiVE5d
J&J’s nipocalimab granted FDA breakthrough designation for Sjögren’s disease
Johnson & Johnson (J&J) has announced that its anti-FcRn antibody nipocalimab has become the first investigational therapy to ...
KTAB Abilene on MSN5d
John Krasinski named People’s Sexiest Man Alive for 2024
John Krasinski is People magazine’s Sexiest Man Alive for 2024. The magazine announced the actor-writer-director as its pick ...
Pharmabiz5d
US FDA grants breakthrough therapy designation to Johnson & Johnson’s nipocalimab to treat adults living with moderate-to-severe Sjögren's disease
Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...
Daily6d
USFDA grants Breakthrough Therapy Designation to Nipocalimab for treatment of adults with moderate-to-severe Sjögren's disease: JnJ
Spring House: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab ...
Vaxcyte provides regulatory updates on VAX-31 programs
Vaxcyte (PCVX) announced positive regulatory updates, including the United States Food and Drug Administration, FDA, clearance of the VAX-31 ...
Seeking Alpha6d
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
Setrusumab (UX143) recently received the FDA's Breakthrough Therapy Designation (BTD) for osteogenesis imperfect following ...
Vaxcyte, Inc.: Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: ...
Pharmaceutical Technology6d
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & ...
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
With BTD, Vaxcyte will have access to all the elements of the FDA’s Fast Track program, as well as the ability to receive guidance and support from the FDA on an efficient drug development program and ...